AWARD NUMBER: W81XWH-16-1-0595

TITLE: Prostate-Specific Membrane Antigen (PSMA) Targeted Bio-orthogonal Therapy for Metastatic Prostate Cancer

PRINCIPAL INVESTIGATOR: Dmitri Artemov., Ph.D.

CONTRACTING ORGANIZATION: Johns Hopkins University Baltimore, MD, 21205-2196

REPORT DATE: October 2017

TYPE OF REPORT: Annual

#### PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

#### DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

RF	EPORT DOC		Form Approved OMB No. 0704-0188					
Public reporting burden for this co	ollection of information is estir	wing instructions, sear	earching existing data sources, gathering and maintaining the					
this burden to Department of Def 4302. Respondents should be a valid OMB control number. <b>PLE</b>	ense, Washington Headquart ware that notwithstanding any	ers Services, Directorate for Infor other provision of law, no persor	mation Operations and Reports ( n shall be subject to any penalty f	(0704-0188), 1215 Jeff for failing to comply wit	ollection of information, including suggestions for reducing erson Davis Highway, Suite 1204, Arlington, VA 22202- h a collection of information if it does not display a currently			
<b>1.REPORT DATE</b> October 2017		2. REPORT TYPE			<b>DATES COVERED</b> 5 Sep 2016 - 14 Sep 2017			
4. TITLE AND SUBTITL		Annual			CONTRACT NUMBER			
Prostate-Specific Membrane Antigen (PSMA) Targeted					GRANT NUMBER			
Bio-orthogonal Therapy for Metastatic Prostate Cancer					1XWH-16-1-0595			
		5c.	PROGRAM ELEMENT NUMBER					
6. AUTHOR(S)		5d.	PROJECT NUMBER					
Dmitri Artemov, Ph.D.					e. TASK NUMBER			
C Mail: dartama2@i	ihmi odu	5f.	f. WORK UNIT NUMBER					
E-Mail: dartemo2@ 7. PERFORMING ORGA		AND ADDRESS(ES)		8. F	PERFORMING ORGANIZATION REPORT			
Johns Hopkins U	Jniversity			1	NUMBER			
School of Medic								
Baltimore, MD,	21205-2196							
9. SPONSORING / MON	IITORING AGENCY N	IAME(S) AND ADDRES	S(ES)	10.	SPONSOR/MONITOR'S ACRONYM(S)			
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012					1. SPONSOR/MONITOR'S REPORT NUMBER(S)			
12. DISTRIBUTION / AV		IENT						
Approved for Public Release; Distribution Unlimited								
13. SUPPLEMENTARY	NOTES							
14. ABSTRACT During the first year of the project we have identified new monoclonal anti-PSMA antibody (mAb), which demonstrated high affinity to the PSMA receptor and excellent targeting of PSMA- expressing prostate cancer cells both <i>in vitro</i> and <i>in vivo</i> . We investigated details of the mAb and therapeutic complexes internalization in these cells and demonstrated rapid perinuclear localization of internalized agents. We have also synthesized and tested click- reactive components for <i>in vivo</i> therapy. First <i>in vivo</i> data for anti-PSMA click-based pretargeting have been obtained with NIR <i>in vivo</i> optical imaging. In addition, all regulatory reviews of the proposed animal procedures have been successfully completed.								
15. SUBJECT TERMS								
Targeted agents, anti-PSMA antibody, image-guided therapy								
16. SECURITY CLASSI	FICATION OF:		17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON USAMRMC			
a. REPORT	b. ABSTRACT	c. THIS PAGE	Unclassified	7	<b>19b. TELEPHONE NUMBER</b> (include area code)			
Unclassified	Unclassified	Unclassified			Standard Form 298 (Rev. 8-98)			

Standard Form 298 (Rev. 8-98 Prescribed by ANSI Std. Z39.18

# **Table of Contents**

# Page

1. Introduction 4	
2. Keywords 4	
3. Accomplishments 4	ŀ
4. Impact 6	)
5. Changes/Problems	
6. Products	,
7. Participants & Other Collaborating Organizations	7
8. Special Reporting Requirements7	7
9. Appendices 7	7

#### 1. Introduction

During the first year of the project we have identified new monoclonal anti-PSMA antibody (mAb), which demonstrated high affinity to the PSMA receptor and excellent targeting of PSMA-expressing prostate cancer cells both *in vitro* and *in vivo*. We investigated details of the mAb and therapeutic complexes internalization in these cells and demonstrated rapid perinuclear localization of internalized agents. We have also synthesized and tested click-reactive components for *in vivo* therapy. First *in vivo* data for anti-PSMA click-based pretargeting have been obtained with NIR *in vivo* optical imaging. To further understand the tumor delivery patterns contrast enhanced MRI was performed in several animals with PC3-Luc and PC3-PIP tumors. In addition, all regulatory reviews of the proposed animal procedures have been successfully completed.

# 2. Keywords

# 3.

Anti-PSMA monoclonal antibody, targeted therapy, *in vivo* imaging, antibody internalization, cytotoxic conjugates, two-component therapy, pretargeting

# 4. Accomplishments

#### What were the major goals of the project?

Specific Aims of the proposal are:

**Aim 1.** Synthesize and characterize anti-PSMA J591 mAb-based pretargeting and albumin based nanocarrier components. Optimize the therapeutic efficacy of the delivery strategy *in vitro* in PSMA(+) and PSMA(-) PCa cells.

**Aim 2.** To evaluate the therapeutic system in subcutaneous and intratibial metastatic mouse models using PSMA(+) C4-2 and PC3-PIP and PSMA(-) PC3 cell lines.

Specifically for the first year of the project the approved SOW includes the following activities:

Subtask 1: Synthesize TCO-functionalized anti-PSMA antibody and tetrazine-functionalized HSA-DM1 carriers.

Subtask 2: Characterize stability, solubility, and affinity of specific binding of components in a panel of PSMA-positive cancer cells.

Subtask 3: Study mechanism of internalization of the therapeutic complexes in PSMA-positive cancer cells.

Subtask 4: Regulatory review of the animal procedures proposed.

#### What was accomplished under these goals?

TCO-fucntionalized anti-PSMA antibodies were synthetized using parent 5D3 mAbs, functionalized TCO moieties for click chemistry reactivity, and fluorophores for microscopy (AF488) and *in vivo* NIR fluorescence imaging (CF680). Examples of *in vitro* and *in vivo* binding of the functionalized antibody in PSMA-expressing (high and low) prostate cancer cells and experimental tumors are shown in Fig. 1.

To synthesize cytotoxic drug carrier components globular albumin molecules were conjugated with PEGylated tetrazine (Tt, reactive group for click chemistry) and microtubule inhibitor mertansine (DM1) therapeutic agent using MCC hetero-bifunctional linker. The high-molecular weight conjugate was purified by ultrafiltration and size-exclusion chromatography.



Mass-spectroscopy of parent albumin, intermediate compounds, and final product are shown in Fig. 2. All compounds were stable for at least 24h in sterile buffers and media at room temperature and at least for 7 days at 4<sup>o</sup>C. Internalization of components was studied in details in PSMA+ PC3-PIP cells and we demonstrated perinuclear localization of the internalized complexes presumably in the centrosome of the target cell (Fig. 3 - green). The internalization mechanism is different from clathrin-mediated endocytosis, as one can see by comparing signals of internalized dextran and mAbs (Fig. 3 - red).



intermediates, and final cytotoxic reactive conjugate.



Figure 3. Confocal microscopy of internalization of therapeutic components by PC3-PIP prostate cancer cells. Green – internalized mAb, red-dextran molecules, blue – cell nuclei.

This new mechanism opens an interesting possibility to deliver therapeutic compounds to the perinuclear location without exposing them (or the carrier) to degradative proteolytic enzymes present in endosomes and lysosomes.

Our most recent NIR imaging data for *in vivo* distribution of pretargeting and drug carrier components are shown in Fig.4.



Deliverables: during the first year of the project we have synthesized and characterized in vivo and in vitro the following therapeutic components:

- (i) 5D3(mAb)-TCO-CF680 for *in vivo* NIR fluorescent imaging
- (ii) 5D3(mAb)-TCO-Alexa488 for confocal microscopy
- (iii) Albumin-PEG4-Tt-CF750 for in vivo NIR fluorescence imaging
- (iv) Albumin-PEG4-Tt-Rhodamine for confocal microscopy
- (v) Albumin-PEG4-Tt-MCC-DM1 cytotoxic drug carrier component

#### How were the results disseminated to communities of interest?

Scientific presentations were given at laboratory seminars and some results presented at JHU ICMIC seminar series

# What do you plan to do during the next reporting period to accomplish the goals?

During the next period of the project (year 2) we will test the synthesized cytotoxic conjugates in cultured prostate cancer cells with different levels of expression of PSMA-receptors. We will optimize the compounds for *in vivo* studies in orthotopic and metastatic mouse models of human prostate cancer. Intratibial models of metastatic prostate cancer will also be developed.

# 5. Impact

# What was the impact on the development of the principal discipline(s) of the project?

Novel two-component pretargeting system for specific therapy of PSMA-expressing prostate cancer can result in high efficacy and significantly reduced toxicity and side effects. Our synthesized therapeutic components (pretargeting and drug-carrier) are a first generation of such a system and are applicable to experimental therapy in animal models. Once optimized and validated future translation to clinic should be feasible.

#### What was the impact on other disciplines?

Nothing to report

#### What was the impact on technology transfer?

Nothing to report

#### What was the impact on society beyond science and technology?

Nothing to report

#### 6. Changes/Problems

In the course of the study we became aware of a novel monoclonal anti-PSMA antibody, 5D3, produced by Dr. Barinka (Institute of Biotechnology CAS, Vestec, Czech Republic), which have been used in the lab of our consultant, Dr. M. Pomper. These antibodies are significantly less expensive then originally proposed J591 mAb, and have been extensively characterized both *in vivo* and *in vitro* and have similar or better affinity to the extracellular domain PSMA target than other anti-PSMA antibodies. The 5D3 antibody is also available in large batches ( $\geq 10$ mg). Therefore we have used and planning to use this mAb in all our *in vitro* and *in vivo* studies for therapeutic PSMA targeting

# 7. Products

Research materials (please see Accomplishments)

# 8. Participants & Other Collaborating Organizations

Name:	Dmitri	Sean Lupold,	Sudath	Colin Huang,	Martin						
	Artemov,	Ph.D.	Hapuarachchige,	B.S.	Pomper,						
	Ph.D.		Ph.D.		M.D./Ph.D.						
Project Role:	PI	Co-	Research	Technician	Consultant						
_		investigator	Associate								
Research											
Identifier:											
Nearest person	3	0.6	6	6							
month worked:											
Contribution to	In vivo	Providing	Chemical	Maintaining	Consultancy in						
the project:	imaging, data	prostate cancer	synthesis and	cell cultures,	PSMA						
	interpretation,	cells,	characterization	performing	targeting and						
	supervising	interpreting in	of therapeutic	routine tests,	imaging						
	personal and	vitro results	components, in	confocal							
	insuring stable		vivo imaging	microscopy							
	workflow			and image							
				processing							
Funding	NIH/NCI	NIH/NCI	NIH/NCI	NIH/NCI	NIH/NCI						
support:											

#### What individuals have worked on the project?

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Nothing to report

# What other organizations were involved as partners?

Nothing to report

# 9. Special Reporting Requirements

Nothing to report

# **10. Appendices**

N/A